Everence Capital Management Inc. acquired a new position in Astrana Health, Inc. (NASDAQ:ASTH – Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 4,690 shares of the company’s stock, valued at approximately $272,000.
Other institutional investors and hedge funds have also bought and sold shares of the company. SG Americas Securities LLC purchased a new stake in Astrana Health in the 3rd quarter worth approximately $680,000. Granite Bay Wealth Management LLC bought a new position in shares of Astrana Health in the 3rd quarter worth approximately $290,000. GAMMA Investing LLC bought a new position in shares of Astrana Health in the 3rd quarter worth approximately $34,000. Handelsbanken Fonder AB bought a new position in shares of Astrana Health in the 3rd quarter worth approximately $492,000. Finally, Central Pacific Bank Trust Division bought a new position in shares of Astrana Health in the 3rd quarter worth approximately $160,000. Hedge funds and other institutional investors own 52.77% of the company’s stock.
Astrana Health Stock Performance
Shares of ASTH opened at $57.90 on Wednesday. The business’s fifty day simple moving average is $53.62 and its two-hundred day simple moving average is $46.13. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 0.62. Astrana Health, Inc. has a 12 month low of $28.86 and a 12 month high of $63.20. The company has a market cap of $3.24 billion, a price-to-earnings ratio of 43.86, a P/E/G ratio of 2.20 and a beta of 1.21.
Analyst Ratings Changes
Several research analysts have recently issued reports on ASTH shares. Stifel Nicolaus increased their target price on Astrana Health from $48.00 to $60.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. Truist Financial increased their target price on Astrana Health from $50.00 to $59.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. KeyCorp began coverage on Astrana Health in a research report on Friday, October 11th. They issued a “sector weight” rating for the company. Robert W. Baird raised their price objective on Astrana Health from $54.00 to $67.00 and gave the company an “outperform” rating in a research report on Thursday, August 15th. Finally, BTIG Research raised their price objective on Astrana Health from $60.00 to $70.00 and gave the company a “buy” rating in a research report on Thursday, October 3rd. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Astrana Health presently has a consensus rating of “Buy” and an average target price of $62.00.
Read Our Latest Stock Report on Astrana Health
Astrana Health Profile
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.
Further Reading
- Five stocks we like better than Astrana Health
- What is the Dow Jones Industrial Average (DJIA)?
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- What is the S&P 500 and How It is Distinct from Other Indexes
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Want to see what other hedge funds are holding ASTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrana Health, Inc. (NASDAQ:ASTH – Free Report).
Receive News & Ratings for Astrana Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrana Health and related companies with MarketBeat.com's FREE daily email newsletter.